Estimating the cure proportion of stage IA lung adenocarcinoma: a population-based study

被引:0
|
作者
Zhixin Huang
Dinghang Chen
Zhinuan Hong
Mingqiang Kang
机构
[1] Fujian Medical University Union Hospital,Department of Thoracic Surgery
[2] Fujian Medical University,Key Laboratory of Cardio
[3] Fujian Province University,Thoracic Surgery
[4] Fujian Medical University,Key Laboratory of Ministry of Education for Gastrointestinal Cancer
[5] Fujian Medical University,Fujian Key Laboratory of Tumor Microbiology
来源
BMC Pulmonary Medicine | / 23卷
关键词
Mixed cure model; Lung adenocarcinoma; Stage IA; Histological subtype; Prognostic analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [31] Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma
    Hattori, Aritoshi
    Hirayama, Shunki
    Matsunaga, Takeshi
    Hayashi, Takuo
    Takamochi, Kazuya
    Oh, Shiaki
    Suzuki, Kenji
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) : 265 - 275
  • [32] Development and validation of a nomogram based on preoperative variables for predicting recurrence-free survival in stage IA lung adenocarcinoma
    Xu, Jiaxi
    Zeng, Hui
    Zhang, Guochao
    Li, Renda
    Yuan, Zhenlong
    Ren, Jingyu
    Huang, Yufei
    Ren, Fangzhou
    Zhang, Hao
    Fei, Kailun
    Feng, Feiyue
    Tan, Fengwei
    THORACIC CANCER, 2023, 14 (31) : 3108 - 3118
  • [33] Deep learning-enhanced radiomics for histologic classification and grade stratification of stage IA lung adenocarcinoma: a multicenter study
    Pei, Guotian
    Wang, Dawei
    Sun, Kunkun
    Yang, Yingshun
    Tang, Wen
    Sun, Yanfeng
    Yin, Siyuan
    Liu, Qiang
    Wang, Shuai
    Huang, Yuqing
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] The Histologic Subtype of Lung Adenocarcinoma Should Not Deter Sublobar Resection for Patients with Clinical Stage IA Lung Cancer
    Kamel, Mohamed
    Narula, Navneet
    Stiles, Brendon
    Nasar, Abu
    Ghaly, Galal
    Rahouma, Mohamed
    Port, Jeffery
    Lee, Paul
    Paul, Subroto
    Altorki, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S432 - S433
  • [35] Impact of the Presence and Proportion of GGO on Survival and Pathological Characteristics in Clinical Stage I Lung Adenocarcinoma
    Katsumata, S.
    Aokage, K.
    Ishii, G.
    Nakasone, S.
    Miyoshi, T.
    Tane, K.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S547 - S547
  • [36] A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma
    Qiu, Zhen-Bin
    Wang, Meng-Min
    Yan, Jin-Hai
    Zhang, Chao
    Wu, Yi-Long
    Zhang, Sheng
    Zhong, Wen-Zhao
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2023, 35 (03) : 594 - 602
  • [37] Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma
    Murakami, Shuji
    Ito, Hiroyuki
    Tsubokawa, Norifumi
    Mimae, Takahiro
    Sasada, Shinsuke
    Yoshiya, Tomoharu
    Miyata, Yoshihiro
    Yokose, Tomoyuki
    Okada, Morihito
    Nakayama, Haruhiko
    LUNG CANCER, 2015, 90 (02) : 199 - 204
  • [38] Survival and Long-Term Cause-Specific Mortality Associated With Stage IA Lung Adenocarcinoma After Wedge Resection vs. Segmentectomy: A Population-Based Propensity Score Matching and Competing Risk Analysis
    Zhao, Mengnan
    Lu, Tao
    Huang, Yiwei
    Yin, Jiacheng
    Jiang, Tian
    Li, Ming
    Yang, Xinyu
    Zhan, Cheng
    Feng, Mingxiang
    Wang, Qun
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [39] MicroRNA expression profile in stage IA lung adenocarcinoma and miR-940 target prediction
    Zhu, Youcai
    Li, Xiaofeng
    Wu, Lixin
    Chen, Huafei
    Xu, Chunwei
    Wei, Jianguo
    Du, Kaiqi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (02): : 1443 - 1452
  • [40] Does the presence of a micropapillary component predict worse prognosis in pathological stage IA lung adenocarcinoma?
    Wang, Yan
    Song, Wenpeng
    Wang, Xin
    Che, Guowei
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 242